BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Regulatory Affairs Market Size to Hit Around US$ 20.5 Billion by 2030

  According to Vision Research Reports, the global Regulatory Affairs market is anticipated to grow at a CAGR of 8.9% during forecast period 2021 to 2030 and expected to hit around US$ 20.5 billion by 2030.

  June 23, 2022

   · 

  11 min read
• Breast Implants Market Size to Surpass Around US$ 5.7 Billion by 2030

  According to Vision Research Reports, the breast implants market size was estimated at US$ 2.5 billion in 2021 and is expected to surpass around US$ 5.7 billion by 2030, poised to grow at a CAGR of 15.5% during forecast period 2022 to 2030.

  June 23, 2022

   · 

  7 min read
• Blood Group Typing Market Size to Surpass USD 5.9 Billion by 2030

  The global blood group typing market was estimated at USD 3.5 billion in 2021 and it is predicted to surpass around USD 5.9 billion by 2030 with a CAGR of 5.97% from 2022 to 2030.

  June 23, 2022

   · 

  6 min read
• Biotech Bay

  NGM Bio to Host the Final of Four Virtual R&D Events on June 29, 2022

  NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it will host the fourth of four virtual R&D events on Wednesday, June 29, 2022, from 11:00 am – 12:30 pm ET.

  June 23, 2022

   · 

  4 min read
• BioCapital

  Novavax’ Nuvaxovid™ COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan for Use in Individuals Aged 18 and Over

  Novavax, Inc. (Nasdaq: NVAX), today announced that the Taiwan Food and Drug Administration has granted emergency use authorization (EUA) for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine in individuals aged 18 years and over.

  June 23, 2022

   · 

  11 min read